What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?

Simply Wall St.09-02

Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (NasdaqGS:CRNX), resulting in Crinetics becoming a wholly owned subsidiary. Crinetics has been delisted from the Nasdaq, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2664689541?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-09-02 10:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664689541","market":"hk","top_or_hot":-1,"title":"What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?","media":"Simply Wall St.","content":"<div>\n<p>Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (NasdaqGS:CRNX), resulting in Crinetics becoming a wholly owned subsidiary. Crinetics has been delisted from the Nasdaq, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/what-does-crinetics-pharmaceuticals-crnx-delisting-mean-afte\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-02 10:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/what-does-crinetics-pharmaceuticals-crnx-delisting-mean-afte><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (NasdaqGS:CRNX), resulting in Crinetics becoming a wholly owned subsidiary. Crinetics has been delisted from the Nasdaq, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/what-does-crinetics-pharmaceuticals-crnx-delisting-mean-afte\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBBQ","symbol_name":"Invesco Nasdaq Biotechnology ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/what-does-crinetics-pharmaceuticals-crnx-delisting-mean-afte","article_id":"2664689541","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/what-does-crinetics-pharmaceuticals-crnx-delisting-mean-afte","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2664689541","pubTimestamp":1788315823,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (NasdaqGS:CRNX), resulting in Crinetics becoming a wholly owned subsidiary.\nCrinetics has been delisted from the Nasdaq, with leadership changes announced as part of its integration into Vertex's operations.\nThe transaction ends Crinetics' status as an independent public company and shifts its future direction under Vertex's control.\n\nFor readers tracking consolidation in biopharma and looking for more stock ideas...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBBQ":"Invesco Nasdaq Biotechnology ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BBH":"VanEck Biotech ETF","CRNX":"Crinetics Pharmaceuticals Inc.","BK4567":"ESG概念","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4585":"ETF&股票定投概念","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","VRTX":"福泰制药","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4007":"制药","GNMX":"Corgi Genomics & Precision Medicine ETF","BK4023":"应用软件","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU0058720904.USD":"联博国际健康护理基金A","VERX":"Vertex, Inc.","BIB":"Ultra纳斯达克生物科","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4588":"碎股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IDNA":"iShares Genomics Immunology and Healthcare ETF","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","IBB":"生物科技指数ETF-iShares Nasdaq","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC"},"translate_title":"收购完成后，Crinetics Pharmaceuticals (CRNX) 退市意味着什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBH":0.6,"PBE":0.6,"IBB":0.6,"BIB":0.6,"CRNX":1.5,"VERX":0.9,"TBXU":0.6,"IBBQ":0.6,"IDNA":0.6,"VRTX":0.9,"GNMX":0.6},"content_text":"Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (NasdaqGS:CRNX), resulting in Crinetics becoming a wholly owned subsidiary. Crinetics has been delisted from the Nasdaq, with leadership changes announced as part of its integration into Vertex's operations. The transaction ends Crinetics' status as an independent public company and shifts its future direction under Vertex's control.  For readers tracking consolidation in biopharma and looking for more stock ideas in this space, the next place to go is 50 high quality undervalued stocks. NasdaqGS:CRNX Earnings & Revenue Growth as at Sep 2026 Crinetics Pharmaceuticals is a US based clinical stage company that develops novel therapeutics for rare endocrine diseases and endocrine related tumors, which gives Vertex exposure to a specialized corner of the pharmaceuticals industry. This positions the acquired business within a focused niche where treatment options can be limited for patients. 2 things going right for Crinetics Pharmaceuticals that this headline doesn't cover. AdvertisementWhat does Vertex’s acquisition actually change for Crinetics Pharmaceuticals? The US$10b acquisition means Crinetics Pharmaceuticals is now a wholly owned subsidiary of Vertex and its stock no longer trades on Nasdaq. Vertex is funding the deal with cash and debt, supported by US$4.5b of committed bridge financing, so Crinetics’ programs now sit inside a much larger balance sheet and commercial platform. Does this change the Crinetics Pharmaceuticals Narrative? The Narrative already framed the US$85 per share cash offer from Vertex as the key anchor for Crinetics Pharmaceuticals and highlighted its endocrine portfolio as a potential fifth commercial pillar for a larger company. With the deal closed and leadership changes announced, that story has shifted from a standalone growth debate to execution inside Vertex’s infrastructure and how well assets like PALSONIFY and atumelnant are integrated. If we take a look at the community Narrative for Crinetics Pharmaceuticals, we can see how this news fits into the bigger investment story. What should you watch next now that Crinetics is part of Vertex? The next concrete checkpoint is how Vertex outlines combined pipeline and commercial priorities for Crinetics’ endocrine programs in upcoming R&D and investor communications, along with any early integration updates from the new leadership team, including Charles Wagner and incoming CFO Jonathan Poole from January 1, 2027. For the full picture including more risks and rewards, check out the complete Crinetics Pharmaceuticals analysis.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664689541","isCrawlerRequest":true}